Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S ( NYSE:NVO), and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most ...

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention the side effects of the drugs.

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

With Robert F. Kennedy Jr. set to be sworn in as HHS secretary later Thursday, one of the first tasks in his new position will be to implement some of the ideas spelled out in his "Make America Health ...

A new study published in JAMA Ophthalmology reveals that weight loss drugs like Ozempic and similar medications could cause three potentially blinding eye conditions. The research identified ...